Lin Zhang

US Patent:

7014866, Mar 21, 2006

Filed:

May 2, 2002

Appl. No.:

10/138071

Inventors:

Martin Howard Infeld - Upper Montclair NJ, US
Wantanee Phuapradit - Clifton NJ, US
Navnit Hargovindas Shah - Clifton NJ, US
Lin Zhang - Piscataway NJ, US

Assignee:

Hoffmann-La Roche Inc. - Nutley NJ

International Classification:

A61K 9/20

US Classification:

424464, 424451, 424470, 514772, 5147723

Abstract:

A solid unit oral pharmaceutical dosage form of amorphous nelfinavir mesylate is provided comprising amorphous nelfinavir mesylate in an amount of from about 400 mg to about 700 mg calculated as nelfinavir base, and a pharmaceutically acceptable water soluble, non-ionic synthetic block copolymer of ethylene oxide and propylene oxide, the copolymer having a melting point of at least about 45 C. and an HLB value at 25 C. of from about 18 to about 29, wherein the copolymer is present from about 40% to about 65% by weight of the nelfinavir mesylate. A hot melt granulation process for making the dosage form is provided.

US Patent:

20050009811, Jan 13, 2005

Filed:

Jul 8, 2004

Appl. No.:

10/886765

Inventors:

Antonio Albano - Clifton NJ, US
Martin Infeld - Upper Montclair NJ, US
Wantanee Phuapradit - Montville NJ, US
Navnit Shah - Clifton NJ, US
Lin Zhang - Bloomfield NJ, US

International Classification:

A61K031/551

US Classification:

514220000

Abstract:

A solid unit oral pharmaceutical dosage form of saquinavir mesylate is provided comprising micronized saquinavir mesylate in an amount of from 250 mg to 800 mg calculated as free base, and a pharmaceutically acceptable binder, disintegrant, and water soluble carrier. A solid unit dosage form of saquinavir mesylate is provided comprising from 60% to 80% micronized saquinavir mesylate based on the mesylate salt, 4% to 8% water soluble binder, a disintegrant and a carrier, wherein each percentage is of the kernel weight.

US Patent:

20080107725, May 8, 2008

Filed:

Oct 2, 2007

Appl. No.:

11/866102

Inventors:

Antonio Albano - Clifton NJ, US
Wantanee Phuapradit - Montville NJ, US
Navnit Shah - Clifton NJ, US
Zhongshui Yu - Bridgewater NJ, US
Lin Zhang - Nutley NJ, US

International Classification:

A61K 9/48
A61K 31/4965

US Classification:

424451000, 514255060

Abstract:

The present invention provides novel pharmaceutical solid dosage forms for oral administration comprising a therapeutically effective amount of an unstable crystalline form or an amorphous form of a therapeutically effective compound micro-embedded into an ionic water-insoluble polymer. The therapeutically effective compounds, which have a tendency to gel, are micro-embedded into an ionic water-insoluble polymer matrix to provide a dosage form having rapid, reproducible, and complete dissolution profiles. These novel solid pharmaceutical dosage forms are useful in the treatment or control of a number of diseases. The present invention also provides a method for treating a disease comprising administering to a subject, in need thereof, a therapeutically effective amount of the novel solid pharmaceutical dosage form. The present invention further provides a method for preparing the pharmaceutical dosage forms.

US Patent:

20090054481, Feb 26, 2009

Filed:

Oct 31, 2008

Appl. No.:

12/262607

Inventors:

Antonio A. Albano - Clifton NJ, US
Martin Howard Infeld - Upper Montclair NJ, US
Wantanee Phuapradit - Montville NJ, US
Navnit Hargovindas Shah - Clifton NJ, US
Lin Zhang - Bloomfield NJ, US

International Classification:

A61K 31/4725

US Classification:

514307

Abstract:

A solid unit oral pharmaceutical dosage form of saquinavir mesylate is provided comprising micronized saquinavir mesylate in an amount of from 250 mg to 800 mg calculated as free base, and a pharmaceutically acceptable binder, disintegrant, and water soluble carrier. A solid unit dosage form of saquinavir mesylate is provided comprising from 60% to 80% micronized saquinavir mesylate based on the mesylate salt, 4% to 8% water soluble binder, a disintegrant and a carrier, wherein each percentage is of the kernel weight.

US Patent:

20200002727, Jan 2, 2020

Filed:

Feb 17, 2018

Appl. No.:

16/486363

Inventors:

- Visp, CH
- New York NY, US
Mark MOFFAT - New York NY, US
Gerald Fries CASPERSON - New York NY, US
Heather Laurence JONES - New York NY, US
Lin ZHANG - New York NY, US

International Classification:

C12N 15/90
C12N 9/12
C12N 15/86
C07K 16/28
C07K 16/30
C07K 14/55
C07K 16/24

Abstract:

The present disclosure relates to a site-specific integration (SSI) mammalian cell that comprises at least two distinct recombination target sites (RTS) wherein two RTS are chromosomally-integrated within the NL1 locus or the NL2 locus. The disclosure also relates to a SSI mammalian cell comprising at least four distinct RTS wherein two RTS are chromosomally-integrated within the NL1 or the NL2 locus and two RTS are chromosomally-integrated within a separate locus. The disclosure also relates to methods for using the SSI mammalian cell to produce recombinant protein expression cell lines that can express difficult to express proteins.

US Patent:

20150072376, Mar 12, 2015

Filed:

Sep 12, 2014

Appl. No.:

14/485353

Inventors:

Robert R. Alfano - Bronx NY, US
Lin Zhang - Brooklyn NY, US
Yang Pu - New York NY, US

International Classification:

G01N 21/64
G01N 33/483

US Classification:

435 34, 4352887

Abstract:

Tryptophan is used as the key native marker in cells to determine the level of aggressiveness of cancer cell lines using the native fluorescence spectroscopy. A ratio R of the fluorescence from tryptophan at 340 nm to that from the NADH at 440-460 nm is demonstrated to be associated with aggressiveness of the cancer cells. The higher the ratio R, the more aggressive the tumor towards metastasis.